References
- World Health Organization. Health equity. [Internet]. 2021. [cited 2021 Aug 12]. Available from: https://www.who.int/health-topics/health-equity#tab=tab_1
- Dahrouge S, Hogg W, Muggah E, et al. Equity of primary care service delivery for low income “sicker” adults across 10 OECD countries. Int J Equity Health. 2018;17(1):182. DOI:https://doi.org/10.1186/s12939-018-0892-z.
- Schoen C, Doty MM. Inequities in access to medical care in five countries: findings from the 2001 Commonwealth fund international health policy survey. Health Policy. 2004;67(3):309–322.
- Rémy V, Zöllner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy. 2015;3.
- World Health Organization. Equity in immunization. [Internet]. 2021. [cited 2021 Sep 6]. Available from: https://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/activities/immunization-systems/equity-in-immunization.
- Bor J, Cohen GH, Galea S. Population health in an era of rising income inequality: USA, 1980-2015. Lancet. 2017;389(10077):1475–1490.
- World Health Organization, United Nations, University of Oxford. Global dashboard for vaccine equity. [Internet]. 2021. [cited 2021 Sep 6]. Available from: https://data.undp.org/vaccine-equity.
- Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140–146. DOI:https://doi.org/10.2471/BLT.07.040089.
- Jayasinghe S, Chiu C, Menzies R, et al. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine. 2015;33(48):6666–6674. DOI:https://doi.org/10.1016/j.vaccine.2015.10.089.
- Public Health England. National Immunisation Programme: health equity audit. [Internet]. 2021. [cited 2022 March 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957670/immnstn-equity_AUDIT_v11.pdf.
- Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005;23(19):2470–2476.
- World Health Organization. Fact sheet. Meningococcal meningitis. [Internet]. 2018. [cited 2021 Aug 11]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis.
- Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–3371. DOI:https://doi.org/10.1016/j.vaccine.2011.02.058.
- Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–783. DOI:https://doi.org/10.1016/S1474-4422(12)70180-1.
- Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782. DOI:https://doi.org/10.1016/j.vaccine.2019.04.020.
- Dastouri F, Hosseini AM, Haworth E, et al. Complications of serogroup B meningococcal disease in survivors: a review. Infect Disord Drug Targets. 2014;14(3):205–212. DOI:https://doi.org/10.2174/1871526515999150320155614.
- O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. DOI:https://doi.org/10.1007/s40265-013-0155-7.
- Harris SL, Tan C, Perez J, et al. Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. NPJ Vaccines. 2020;5(1):8. DOI:https://doi.org/10.1038/s41541-019-0154-0.
- Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–7550. DOI:https://doi.org/10.1016/j.vaccine.2020.09.050.
- Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):e1661–e1668. DOI:https://doi.org/10.1093/cid/ciaa1244.
- Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018;36(45):6867–6874. DOI:https://doi.org/10.1016/j.vaccine.2018.05.081.
- Leduc I, Connolly KL, Begum A, et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 2020;16(12):e1008602. DOI:https://doi.org/10.1371/journal.ppat.1008602.
- Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498. DOI:https://doi.org/10.1016/j.jinf.2020.05.079.
- Trzewikoswki de Lima G, De Gaspari E. Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged? J Aging Res. 2019;2019:9287121.
- Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia (Nathan). 2019;11(1):3.
- Deghmane AE, Taha S, Taha MK. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect Dis (Lond). 2022;54(1):1–7.
- Parent du Chatelet I, Deghmane AE, Antona D, et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect. 2017;74(6):564–574. DOI:https://doi.org/10.1016/j.jinf.2017.02.011.
- Santé publique France. Les infections invasives à méningocoque en France en 2019. [cited 2022 March 1]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-prevention-vaccinale/infections-invasives-a-meningocoque/documents/bulletin-national2/les-infections-invasives-a-meningocoque-en-france-en-2019.
- Smith HV, Jennison AV. Changing epidemiology of invasive meningococcal disease in Australia 1994-2016. Microbiol Aust. 2017;38(4):184–186.
- Lahra MM, George C, Shoushtari M, et al. Communicable diseases intelligence. Volume 45. Australian Meningococcal Surveillance Programme annual report, 2020. [Internet]. 2021. [cited 2021 Sep 6]. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-menganrep.htm.
- World Health Organization. Defeating meningitis by 2030: a global road map. [Internet]. 2021. [cited 2021 Aug 11]. Available from: https://www.who.int/publications/i/item/9789240026407.**WHO roadmap to defeat meningitis worldwide by 2030, with equity as a guiding principle.
- European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases. [Internet]. [cited 2021 Apr 1]. Available from: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=36.
- Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–29. DOI:https://doi.org/10.1016/j.vaccine.2009.04.067.
- Bijlsma MW, Bekker V, Brouwer MC, et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect Dis. 2014;14(9):805–812. DOI:https://doi.org/10.1016/S1473-3099(14)70806-0.
- Garrido-Estepa M, León-Gómez I, Herruzo R, et al. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32(22):2604–2609. DOI:https://doi.org/10.1016/j.vaccine.2014.03.010.
- Bennett D, O’Lorcain P, Morgan S, et al. Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. Epidemiol Infect. 2019;147:e142.
- Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–585. DOI:https://doi.org/10.1093/cid/ciu881.
- Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14). DOI:https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800245.
- Campbell H, Edelstein M, Andrews N, et al. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016. Emerg Infect Dis. 2017;23(7):1184–1187. DOI:https://doi.org/10.3201/eid2307.170236.
- Ladhani SN, Ramsay M, Borrow R, et al. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91–95. DOI:https://doi.org/10.1136/archdischild-2015-308928.
- Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3):469.
- Peterson ME, Li Y, Bita A, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9(1):010409. DOI:https://doi.org/10.7189/jogh.09.010409.
- Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018. [Internet]. 2018. [cited 2020 May 1]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf.
- Brooks R, Woods CW, Benjamin DK Jr., et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49–54. DOI:https://doi.org/10.1086/504804.
- Andrade AL, Minamisava R, Tomich LM, et al. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine. 2017;35(16):2025–2033. DOI:https://doi.org/10.1016/j.vaccine.2017.03.010.
- Villena R, Valenzuela MT, Bastías M, et al. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37(46):6915–6921. DOI:https://doi.org/10.1016/j.vaccine.2019.09.050.
- Mowlaboccus S, Jolley KA, Bray JE, et al. Clonal expansion of new penicillin-resistant clade of Neisseria meningitidis serogroup W clonal complex 11, Australia. Emerg Infect Dis. 2017;23(8):1364–1367. DOI:https://doi.org/10.3201/eid2308.170259.
- Sudbury EL, O’Sullivan S, Lister D, et al. Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017. Emerg Infect Dis. 2020;26(7):1355–1363. DOI:https://doi.org/10.3201/eid2607.181941.
- Li J, Shao Z, Liu G, et al. Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76(5):429–437. DOI:https://doi.org/10.1016/j.jinf.2018.01.007.
- Li J, Li Y, Shao Z, et al. Surveillance of meningococcal disease in China, 2009. Dis Surveill. 2010;25(10):770–774.
- Zhang Y, Wei D, Guo X, et al. Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis. J Glob Health. 2016;6(2):020409. DOI:https://doi.org/10.7189/jogh.06.020409.
- Aye AMM, Bai X, Borrow R, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698–711. DOI:https://doi.org/10.1016/j.jinf.2020.07.025.
- Mustapha MM, Harrison LH. Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges. Hum Vaccin Immunother. 2018;14(5):1107–1115.
- Omoleke SA, Alabi O, Shuaib F, et al. Environmental, economic and socio-cultural risk factors of recurrent seasonal epidemics of cerebrospinal meningitis in Kebbi state, northwestern Nigeria: a qualitative approach. BMC Public Health. 2018;18(Suppl 4):1318. DOI:https://doi.org/10.1186/s12889-018-6196-9.
- Caugant DA, Kristiansen PA, Wang X, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One. 2012;7(9):e46019. DOI:https://doi.org/10.1371/journal.pone.0046019.
- LaForce FM, Okwo-Bele JM. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood). 2011;30(6):1049–1057.
- Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867–872. DOI:https://doi.org/10.1016/S1473-3099(17)30301-8.
- Topaz N, Caugant DA, Taha MK, et al. Phylogenetic relationships and regional spread of meningococcal strains in the meningitis belt, 2011-2016. EBioMedicine. 2019;41:488–496.
- Funk A, Uadiale K, Kamau C, et al. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Curr. 2014;6:ecurrents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518
- Kretz CB, Retchless AC, Sidikou F, et al. Whole-genome characterization of epidemic Neisseria meningitidis serogroup C and resurgence of serogroup W, Niger, 2015. Emerg Infect Dis. 2016;22(10):1762–1768. DOI:https://doi.org/10.3201/eid2210.160468.
- Taha MK, Presa J, Serra L. A review of the epidemiology of invasive meningococcal disease and vaccination strategies in North Africa. Int J Infect Dis. 2021;104:189–197.
- Meiring S, Cohen C, de Gouveia L, et al. Declining incidence of invasive meningococcal disease in South Africa: 2003-2016. Clin Infect Dis. 2019;69(3):495–504. DOI:https://doi.org/10.1093/cid/ciy914.
- Martinon-Torres F, Taha M-K, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. [cited 2021 Sept 20]:[1–14p]. DOI:https://doi.org/10.1080/20477724.2021.1972663.
- Minister of Health of the Czech Republic. Sbírka Zákonů. Česká Republika. Rozeslána dne 12. října 2021. Částka 164. [Internet]. 2021. [cited 2021 Dec 20]. Available from: https://aplikace.mvcr.cz/sbirka-zakonu/ViewFile.aspx?type=c&id=39232.
- Stuart JM, Middleton N, Gunnell DJ. Socioeconomic inequality and meningococcal disease. Commun Dis Public Health. 2002;5(4):327–328.
- Fone DL, Harries JM, Lester N, et al. Meningococcal disease and social deprivation: a small area geographical study in Gwent, UK. Epidemiol Infect. 2003;130(1):53–58. DOI:https://doi.org/10.1017/S095026880200794X.
- Heyderman RS, Ben-Shlomo Y, Brennan CA, et al. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89(11):1064–1068. DOI:https://doi.org/10.1136/adc.2003.036004.
- Williams CJ, Willocks LJ, Lake IR, et al. Geographic correlation between deprivation and risk of meningococcal disease: an ecological study. BMC Public Health. 2004;4(1):30. DOI:https://doi.org/10.1186/1471-2458-4-30.
- Olowokure B, Onions H, Patel D, et al. Geographic and socioeconomic variation in meningococcal disease: a rural/urban comparison. J Infect. 2006;52(1):61–66. DOI:https://doi.org/10.1016/j.jinf.2005.01.013.
- Stanton MC, Taylor-Robinson D, Harris D, et al., Meningococcal disease in children in Merseyside, England: a 31 year descriptive study. PLoS One.2011;6(10): e25957. https://doi.org/10.1371/journal.pone.0025957
- Taha MK, Weil-Olivier C, Bouée S, et al., Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17(6): 1858–1866. https://doi.org/10.1080/21645515.2020.1849518
- Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000;19(10):983–990. DOI:https://doi.org/10.1097/00006454-200010000-00009.
- McCall BJ, Neill AS, Young MM. Risk factors for invasive meningococcal disease in southern Queensland, 2000-2001. Intern Med J. 2004;34(8):464–468.
- Vallejo-Aparicio L, Carmo M, Callejo D, et al. The relationship between the income per capita level of families and the access to multicomponent meningococcal serogroup B (4CMenB) vaccination in Spain. Presented at the X Congreso Sociedad Espanola de Infectologia Pediatrica y XII Reunion Hispano-Mexicana de Infectologia Pediatrica; 2021 March 11–13; Virtual meeting.
- Taylor KA, Stocks N, Marshall HS. The missing link: family physician perspectives on barriers and enablers to prescribing a new meningococcal B vaccine and other recommended, non-government funded vaccines. Vaccine. 2014;32(33):4214–4219.
- Mbaeyi S, Bozio C, Duffy J. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1–41.
- Lu PJ, Yankey D, Jeyarajah J, et al. Association of health insurance status and vaccination coverage among adolescents 13-17 years of age. J Pediatr. 2018;195:256–262.e1.
- Huang L, Goren A, Lee LK, et al. Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations. Hum Vaccin Immunother. 2020;16(4):933–944. DOI:https://doi.org/10.1080/21645515.2019.1682845.
- Watkins E, Feemster K. Factors associated with uptake of meningococcus B vaccination after an ACIP category B recommendation. Open Forum Infect Dis. 2018;5(Suppl 1):S737.
- Srivastava A, Dempsey A, Galitsky A, et al. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States. BMC Public Health. 2020;20(1):1109. DOI:https://doi.org/10.1186/s12889-020-09181-8.
- Bart S, Eberhart M, Feemster K Impact of a category B recommendation: meningococcal B (MenB) vaccine uptake among adolescents in Philadelphia county. Pediatric Academic Societies Meeting; 2018 May 5–8; Toronto, Canada.
- Fergie J, Howard A, Huang L, et al. Implementation experience with meningococcal serogroup B vaccines in the United States: impact of a nonroutine recommendation. Pediatr Infect Dis J. 2021;40(3):269–275. DOI:https://doi.org/10.1097/INF.0000000000003033.
- United States Government. Medicaid.gov. Keeping America healthy. [Internet]. 2021 [cited 2021 Dec 15]. Available from: www.medicaid.gov.
- Blagden S, Hungerford D, Limmer M. Meningococcal vaccination in primary care amongst adolescents in North West England: an ecological study investigating associations with general practice characteristics. J Public Health (Oxf). 2019;41(1):149–157.
- Tiley K, White J, Andrews N, et al., What school-level and area-level factors influenced HPV and MenACWY vaccine coverage in England in 2016/2017? An ecological study. BMJ Open. 2019;9(7): e029087. https://doi.org/10.1136/bmjopen-2019-029087.
- Fletcher R, Wilkinson E, Cleary P, et al. Did school characteristics affect the uptake of meningococcal quadrivalent vaccine in Greater Manchester, United Kingdom? Public Health. 2019;171:24–30. DOI:https://doi.org/10.1016/j.puhe.2019.03.018
- Department for Communities and Local Government. English Indices of Deprivation 2015. File 10: local Authority District Summaries. [Internet]. 2015. [cited 2021 Dec 15]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/464464/File_10_ID2015_Local_Authority_District_Summaries.xlsx.
- Bröker M, Emonet S, Fazio C, et al. Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother. 2015;11(9):2281–2286. DOI:https://doi.org/10.1080/21645515.2015.1051276.
- Joint Committee on Vaccination and Immunisation. JCVI interim position statement on use of Bexsero meningococcal B vaccine in the UK. July 2013. [Internet]. 2013. [cited 2020 May 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf.
- Moxon R, Snape MD. The price of prevention: what now for immunisation against meningococcus B? Lancet. 2013;382(9890):369–370.
- Blewitt J. Immunisation against meningococcus B. Lancet. 2013;382(9895):857–858.
- Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero meningococcal B vaccine in the UK. March 2014. [Internet]. 2014. [cited 2020 May 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf.
- Christensen H, Trotter CL, Hickman M, et al., Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 349: g5725. 2014. https://doi.org/10.1136/bmj.g5725.
- Christensen H, Al-Janabi H, Levy P, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297–309. DOI:https://doi.org/10.1007/s10198-019-01129-z.
- Stawasz A, Huang L, Kirby P, et al. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination’s full social and economic benefits. Front Public Health. 2020;8:261.
- Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104. DOI:https://doi.org/10.1016/j.jval.2020.09.004.
- Gasparini R, Landa P, Amicizia D, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12(8):2148–2161. DOI:https://doi.org/10.1080/21645515.2016.1160177.
- Sevilla J, Tortorice D, Kantor D, et al. PIN43 Lifecycle-model-based economic evaluation of infant meningitis B vaccination in the UK. Value Health. 2019;22(Suppl 3):S647. DOI:https://doi.org/10.1016/j.jval.2019.09.1286.
- Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021;24(1):86–90.
- Boccalini S, Zanella B, Landa P, et al. Why the anti-meningococcal B vaccination during adolescence should be implemented in Italy: an overview of available evidence. Microorganisms. 2020;8(11):1681. DOI:https://doi.org/10.3390/microorganisms8111681.
- Gras-Le Guen C, Vignier N, Kochert F, et al. Why should the meningococcal B vaccine be recommended, and therefore reimbursed, for infants in France? Infect Dis Now. 2021; 51(5) 407–409. https://doi.org/10.1016/j.idnow.2021.05.001
- Haute Autorité de Santé. Stratégie de vaccination pour la prévention des infections invasives à méningocoques: le sérogroupe B et la place de BEXSERO®. [Internet]. 2021. [cited 2021 Aug 11]. Available from: https://www.has-sante.fr/jcms/p_3066921/fr/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexsero.
- Anon. SIGLO XXI. La Asociación Española contra la Meningitis celebra la incorporación de la vacuna contra esta enfermedad en Cataluña y Andalucía. [Internet]. 2021. Accessed 22 November 2021. Available from: https://www.diariosigloxxi.com/texto-s/mostrar/431256/asociacion-espanola-contra-meningitis-celebra-incorporacion-vacuna-contra-esta-enfermedad-cataluna-andalucia.
- Brady MT. Strength and clarity of vaccine recommendations influence providers’ practice. Pediatrics. 2018;142(3). DOI:https://doi.org/10.1542/peds.2018-1633
- Kempe A, Allison MA, MacNeil JR, et al. Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3). DOI:https://doi.org/10.1542/peds.2018-0344.
- Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2019. Morb Mortal Wkly Rep. 2020;69(33):1109–1116. DOI:https://doi.org/10.15585/mmwr.mm6933a1.
- Public Health England and National Health Service Digital. Childhood vaccination coverage statistics - England 2019-20. [Internet]. 2020. [cited 2021 Jul 8]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-statistics/england---2019-20.
- Stewart C Coverage of meningococcus B vaccine among 24 months old children in Italy as of 2019, by region. [Internet]. 2021. [cited 2021 Aug 12]. Available from: https://www.statista.com/statistics/987248/coverage-of-meningococcus-b-vaccine-in-italy/.
- Esposito S, Principi N, Cornaglia G. Barriers to the vaccination of children and adolescents and possible solutions. Clin Microbiol Infect. 2014;20(Suppl 5):25–31.
- Usher AD. A beautiful idea: how COVAX has fallen short. Lancet. 2021;397(10292):2322–2325.
- World Health Organization. Call to action: vaccine equity. [Internet]. 2021. [cited 2021 Aug 12]. Available from: https://www.who.int/campaigns/vaccine-equity/vaccine-equity-declaration.
- Health Resources and Services Administration. Ensuring Equity in COVID-19 Vaccine Distribution. [Internet]. 2022. [cited 2022 Mar 3]. Available from: https://www.hrsa.gov/coronavirus/health-center-program.
- Department of Health and Social Care. Universal vaccination of children and young people aged 12 to 15 years against COVID-19. [Internet]. 2021. [cited 2021 Sep 1]. Available from: https://www.gov.uk/government/publications/universal-vaccination-of-children-and-young-people-aged-12-to-15-years-against-covid-19/universal-vaccination-of-children-and-young-people-aged-12-to-15-years-against-covid-19.
- Taine M, Offredo L, Drouin J, et al. Mandatory infant vaccinations in France during the COVID-19 pandemic in 2020. Front Pediatr. 2021;9:666848.
- McDonald HI, Tessier E, White JM, et al. Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020. Euro Surveill. 2020;25(19). DOI:https://doi.org/10.2807/1560-7917.ES.2020.25.19.2000848.
- Saxena K, Marden JR, Carias C, et al. Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States. Curr Med Res Opin. 2021;37(12):2077–2087. DOI:https://doi.org/10.1080/03007995.2021.1981842.
- Taha MK, Deghmane AE. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res Notes. 2020;13(1):399.
- Bonanni P, Villani A, Scotti S, et al. The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: a continuing example of impact on public health policies. Vaccine. 2021;39(8):1183–1186. DOI:https://doi.org/10.1016/j.vaccine.2021.01.019.
- Meningitis Research Foundation. Meningitis progress tracker. [Internet]. 2021. [cited 2021 Dec 15]. Available from: https://www.meningitis.org/mpt.